Risk-Benefit Assessment of Opioids in Chronic Noncancer Pain

被引：0
|
作者：
Bernard Bannwarth
机构：
[1] Victor Segalen University,Department of Rheumatology, Pellegrin Hospital, and Laboratory of Therapeutics
[2] Hôpital Pellegrin,Service de Rhumatologie
来源：
Drug Safety | 1999年 / 21卷
关键词：
Morphine; Adis International Limited; Paracetamol; Neuropathic Pain; Tramadol;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Opioids have been accepted as appropriate treatment for acute and cancer pain, but their role in the management of chronic nonmalignant pain is the subject of much debate, mainly due to concerns about waning efficacy, the potential for neuropsychological impairment and the development of drug addiction.
引用
下载
收藏
页码：283 / 296
页数：13
相关论文
共 50 条
  • [31] A Risk-Benefit Assessment of Antileukotrienes in Asthma
    Lewis J. Smith
    Drug Safety, 1998, 19 : 205 - 218
  • [32] Risk-benefit ratio or risk-benefit nonsense?
    Ernst, E
    Resch, KL
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 1996, 49 (10) : 1203 - 1204
  • [33] A RISK-BENEFIT ASSESSMENT OF RISPERIDONE IN SCHIZOPHRENIA
    CURTIS, VA
    KERWIN, RW
    DRUG SAFETY, 1995, 12 (02) : 139 - 145
  • [34] A RISK-BENEFIT ASSESSMENT OF TACROLIMUS IN TRANSPLANTATION
    WINKLER, M
    CHRISTIANS, U
    DRUG SAFETY, 1995, 12 (05) : 348 - 357
  • [35] A RISK-BENEFIT ASSESSMENT OF TAMOXIFEN THERAPY
    CATHERINO, WH
    JORDAN, VC
    DRUG SAFETY, 1993, 8 (05) : 381 - 397
  • [36] A risk-benefit assessment of abciximab in angioplasty
    Kleiman, NS
    DRUG SAFETY, 1999, 20 (01) : 43 - 57
  • [37] THE RISK-BENEFIT ASSESSMENT OF ANTIDEPRESSANT DRUGS
    HENRY, JA
    MARTIN, AJ
    MEDICAL TOXICOLOGY AND ADVERSE DRUG EXPERIENCE, 1987, 2 (06): : 445 - 462
  • [38] A risk-benefit assessment of drugs used for neonatal chronic lung disease
    Sweet, DG
    Halliday, HL
    DRUG SAFETY, 2000, 22 (05) : 389 - 404
  • [39] A Risk-Benefit Assessment of Drugs Used for Neonatal Chronic Lung Disease
    David G. Sweet
    Henry L. Halliday
    Drug Safety, 2000, 22 : 389 - 404
  • [40] A PRELIMINARY RISK-BENEFIT ASSESSMENT OF PACLITAXEL
    BITTON, RJ
    FIGG, WD
    REED, E
    DRUG SAFETY, 1995, 12 (03) : 196 - 208
12345